Clinical Trial: HB1801 Combined Treatment of HER2-positive Breast Cancer

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07116824) titled 'HB1801 Combined Treatment of HER2-positive Breast Cancer' on Aug. 07.

Brief Summary: This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.

Study Start Date: Sept. 15

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: HB1801

HB1801 is administered by intravenous infusion.

DRUG: Trastuzumab

Trastuzumab is administered by intravenous infusion, 8mg/kg loading dose and then 6mg/kg per cycle, Q3W.

DRUG: Pertuzumab

Pertuzumab is administered by intravenous infus...